Cevipabulin

SKU: orb1710085

Description

Cevipabulin (TTI-237) is a microtubule-targeting antitumor agent that competitively inhibits vinblastine binding to tubulin with an IC50 of 18-40 nM. This compound has demonstrated cytotoxic activity in vitro against human cancer cell lines and has been evaluated in vivo for its potential in oncology research, particularly in studies investigating mitotic disruption and apoptosis.

Research Area

Signal Transduction

Key Properties

• CAS Number: 849550-05-6
• MW: 464.82
• Purity: 99.83% (May vary between batches)
• Formula: C₁₈H₁₈ClF₅N₆O
• SMILES: [H][C@@](C)(Nc1c(c(Cl)nc2ncnn12)-c1c(F)cc(OCCCNC)cc1F)C(F)(F)F
• Target: Microtubule Associated
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.15 mM);DMSO:9 mg/mL (19.36 mM)

Bioactivity

• Target IC50:
  Microtubule (human tumor cells):18-40 nM
• In Vivo:
  In mice, Cevipabulin ( 5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles; i.v. and p.o.) is active against human tumor xenografts and showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg .
• In Vitro:
  Cevipabulin (0-50 nM, 72 hours) exhibits significant activity (IC50s: 18-40 nM) against ovarian, breast, prostate, and cervical tumor cell lines. At low concentrations (20-40 nM), it induces sub-G1 nuclei, while concentrations above 50 nM result in a pronounced G2-M block .

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Cevipabulin, microtubule, Microtubule Associated, microtubule in human tumor cells, MicrotubuleAssociated, TTI 237, TTI237, TTI-237

Compound Identifiers

PubChem CID

11488110